On Tuesday, Rapid Dose Therapeutics Corp.(CSE: DOSE, Forum) announced that is has been issued a micro-processing licence by Health Canada for its Burlington, Ontario facility. The Company is now able to produce its QuickStrip cannabis products for both the Canadian medical and recreational markets.
For more on this news, click here.
The Canadian life sciences Company recently released its Q2 2019 financial results, highlighting revenue of more than $914,000 and profits exceeding $909,000.
FULL DISCLOSURE: Rapid Dose Therapeutics Corp. is a client of Stockhouse Publishing.